ADVANZ PHARMA announces launch of MYTOLAC® in Germany, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

ADVANZ PHARMA announces launch of MYTOLAC^® in Germany, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Bielefeld, Germany, 21 July 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYTOLAC® (lanreotide) in Germany, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and symptoms associated with neuroendocrine tumours.¹*

Acromegaly is a rare disease caused by excessive Growth Hormone (GH) secretion. It is usually diagnosed in adults aged 30 to 50, although can affect people at any age, and is characterised by quick tissue and bone growth, as well as a wide range of other symptoms.² Neuroendocrine tumours (NETs) are rare tumours that can appear anywhere in the neuroendocrine system, the system that controls hormones.³ When a NET is in the gastroenteropancreatic (GEP) system (digestive tract or pancreas) it is known as a GEP-NET.⁴

David Johnson, Global Director, Commercial Excellence, ADVANZ PHARMA said: “Until now, prescriber choice has been limited. The launch of a generic alternative means we are able to improve access and choice while helping to drive down costs.”

Paul Burden, Chief Commercial Officer, Strategic Business Unit, said: “At ADVANZ PHARMA, we have a deep-rooted and specialist knowledge in the off-patent and complex medicine space, enabling us to create a wider choice of more affordable products. This provides hospitals and healthcare professionals with the opportunity to free up budget to spend elsewhere, delivering value and benefit to patients, healthcare providers and healthcare systems as a whole.

“It is through our successful partnerships with regulators, manufacturers and distributors across the region that today’s news has been made possible. We’re proud to announce the launch of this medicine in Germany today and look forward to expanding this to other countries across Europe in the near future.

“This launch is the first of what we hope will be many, as we continue to expand into the complex and value-added medicines space, to the benefit of healthcare professionals and patients in Europe.”